ROBBYN CEASAR: Open Payments
NPI 1235489758 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,917 in 77 payments from 16 companies in 2025. Trend: 2023 $813 · 2024 $1,886 · 2025 $1,917
Food & beverage: $1,917
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $475 |
| Ardelyx, Inc. | 10 | $316 |
| Madrigal Pharmaceuticals | 5 | $238 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $192 |
| Janssen Biotech, Inc. | 9 | $185 |
| Phathom Pharmaceuticals, Inc. | 3 | $168 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Novo Nordisk Inc | 2 | $57 |
| Ipsen Biopharmaceuticals, Inc | 2 | $48 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
Products named: IBSRELA, REZDIFFRA, XIFAXAN, TREMFYA, RINVOQ, VOQUEZNA, SKYRIZI, CREON.
Industry payments across GA — which companies pay providers there.
